Sarah J. Lord

Sarah J. Lord

Auto-generated profile, based on publicly available information

Sarah J. Lord

St. Vincent’s Centre for Applied Medical Research, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
CLChee Khoon Lee
Chee Khoon Lee
JMJohnathan Man
Johnathan Man
SLSally Lord
Sally Lord
MLMatthew Links
Matthew Links
VGVal Gebski
Val Gebski
JYJames Chih-Hsin Yang
James Chih-Hsin Yang

1 July 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
NHNehmat Houssami
Nehmat Houssami
SCStefano Ciatto
Stefano Ciatto
PMPetra Macaskill
Petra Macaskill
SLSarah J. Lord
Sarah J. Lord
RWRuth M. Warren
Ruth M. Warren
LILes Irwig
Les Irwig
Purpose We review the evidence on magnetic resonance imaging (MRI) in staging the affected breast to determine its accuracy and impact on treatment. Methods Systematic review and meta-analysis of the accuracy of MRI in detection of multifocal (MF) and/or multicentric (MC) cancer not identified on conventional imaging. We estimated summary receiver operating characteristic curves, positive predictive value (PPV), true-positive (TP) to false positive (FP) ratio, and examined their variability according to quality criteria. Pooled estimates of the proportion of women whose surgery was altered were calculated. Results Data from 19 studies showed MRI detects additional disease in 16% of women with breast cancer (N = 2,610). MRI incremental accuracy differed according to the reference standard (RS; P = .016) decreasing from 99% to 86% as the quality of the RS increased. Summary PPV was 66% (95% CI, 52% to 77%) and TP:FP ratio was 1.91 (95% CI, 1.09 to 3.34). Conversion from wide local excision (WLE) to mastectomy was 8.1% (95% CI, 5.9 to 11.3), from WLE to more extensive surgery was 11.3% in MF/MC disease (95% CI, 6.8 to 18.3). Due to MRI-detected lesions (in women who did not have additional malignancy on histology) conversion from WLE to mastectomy was 1.1% (95% CI, 0.3 to 3.6) and from WLE to more extensive surgery was 5.5% (95% CI, 3.1 to 9.5). Conclusion MRI staging causes more extensive breast surgery in an important proportion of women by identifying additional cancer, however there is a need to reduce FP MRI detection. Randomized trials are needed to determine the clinical value of detecting additional disease which changes surgical treatment in women with apparently localized breast cancer.

1 February 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
CLChee Khoon Lee
Chee Khoon Lee
JMJohnathan Man
Johnathan Man
SLSally Lord
Sally Lord
WCWendy Cooper
Wendy Cooper
MLMatthew Links
Matthew Links
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
Advanced non–small cell lung carcinoma (NSCLC) is an incurable disease that is associated with a poor prognosis. Globally, it is the leading cause of cancer-related death.1 Docetaxel has been the standard of care for advanced NSCLC following disease progression with platinum doublet chemotherapy.2,3 However, docetaxel is associated with only modest efficacy but substantial toxicity. With the recent advancement in immune checkpoint inhibitor therapies4-8 that target the PD-L1 (programmed cell death 1 ligand 1) and PD-1 (programmed cell death 1) pathways, these agents have recently replaced docetaxel as the new standard second or later line of treatment.

10 June 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CLChee Khoon Lee
Chee Khoon Lee
YWYI-LONG WU
YI-LONG WU
PDPei Ni Ding
Pei Ni Ding
SLSarah J. Lord
Sarah J. Lord
AIAkira Inoue
Akira Inoue
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
Purpose: We examined the impact of different epidermal growth factor receptor (EGFR) mutations and clinical characteristics on progression-free survival (PFS) in patients with advanced EGFR-mutated non–small-cell lung cancer treated with EGFR tyrosine kinase inhibitors (TKIs) as first-line therapy. Patients and Methods: This meta-analysis included randomized trials comparing EGFR TKIs with chemotherapy. We calculated hazard ratios (HRs) and 95% CIs for PFS for the trial population and prespecified subgroups and calculated pooled estimates of treatment efficacy using the fixed-effects inverse-variance-weighted method. All statistical tests were two sided. Results: In seven eligible trials (1,649 patients), EGFR TKIs, compared with chemotherapy, significantly prolonged PFS overall (HR, 0.37; 95% CI, 0.32 to 0.42) and in all subgroups. For tumors with exon 19 deletions, the benefit was 50% greater (HR, 0.24; 95% CI, 0.20 to 0.29) than for tumors with exon 21 L858R substitution (HR, 0.48; 95% CI, 0.39 to 0.58; Pinteraction < .001). Never-smokers had a 36% greater benefit (HR, 0.32; 95% CI, 0.27 to 0.37) than current or former smokers (HR, 0.50; 95% CI, 0.40 to 0.63; Pinteraction < .001). Women had a 27% greater benefit (HR, 0.33; 95% CI, 0.28 to 0.38) than men (HR, 0.45; 95% CI, 0.36 to 0.55; treatment-sex interaction P = .02). Performance status, age, ethnicity, and tumor histology did not significantly predict additional benefit from EGFR TKIs. Conclusion: Although EGFR TKIs significantly prolonged PFS overall and in all subgroups, compared with chemotherapy, greater benefits were observed in those with exon 19 deletions, never-smokers, and women. These findings should enhance drug development and economic analyses, as well as the design and interpretation of clinical trials.

16 May 2017 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
JPJohn W. Pickering
John W. Pickering
MTMartin P. Than
Martin P. Than
LCLouise Cullen
Louise Cullen
SASally Aldous
Sally Aldous
EAEwoud ter Avest
Ewoud ter Avest
JYJoanna Young
Joanna Young
This article has been corrected. The original version (PDF) is appended to this article as a Supplement. High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes used to rapidly rule out acute myocardial infarction (AMI). To estimate the ability of a single hs-cTnT concentration below the limit of detection (<0.005 µg/L) and a nonischemic electrocardiogram (ECG) to rule out AMI in adults presenting to the emergency department (ED) with chest pain. EMBASE and MEDLINE without language restrictions (1 January 2008 to 14 December 2016). Cohort studies involving adults presenting to the ED with possible acute coronary syndrome in whom an ECG and hs-cTnT measurements were obtained and AMI outcomes adjudicated during initial hospitalization. Investigators of studies provided data on the number of low-risk patients (no new ischemia on ECG and hs-cTnT measurements <0.005 µg/L) and the number who had AMI during hospitalization (primary outcome) or a major adverse cardiac event (MACE) or death within 30 days (secondary outcomes), by risk classification (low or not low risk). Two independent epidemiologists rated risk of bias of studies. Of 9241 patients in 11 cohort studies, 2825 (30.6%) were classified as low risk. Fourteen (0.5%) low-risk patients had AMI. Sensitivity of the risk classification for AMI ranged from 87.5% to 100% in individual studies. Pooled estimated sensitivity was 98.7% (95% CI, 96.6% to 99.5%). Sensitivity for 30-day MACEs ranged from 87.9% to 100%; pooled sensitivity was 98.0% (CI, 94.7% to 99.3%). No low-risk patients died. Few studies, variation in timing and methods of reference standard troponin tests, and heterogeneity of risk and prevalence of AMI across studies. A single hs-cTnT concentration below the limit of detection in combination with a nonischemic ECG may successfully rule out AMI in patients presenting to EDs with possible emergency acute coronary syndrome. Emergency Care Foundation.

20 November 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MBMeagan Elizabeth Brennan
Meagan Elizabeth Brennan
NHNehmat Houssami
Nehmat Houssami
SLSarah Lord
Sarah Lord
PMPetra Macaskill
Petra Macaskill
LILes Irwig
Les Irwig
SCStefano Ciatto
Stefano Ciatto
Purpose Preoperative magnetic resonance imaging (MRI) is increasingly used for staging women with breast cancer, including screening for occult contralateral cancer. This article is a review and meta-analysis of studies reporting contralateral MRI in women with newly diagnosed invasive breast cancer. Methods We systematically reviewed the evidence on contralateral MRI, calculating pooled estimates for positive predictive value (PPV), true-positive:false-positive ratio (TP:FP), and incremental cancer detection rate (ICDR) over conventional imaging. Random effects logistic regression examined whether estimates were associated with study quality or clinical variables. Results Twenty-two studies reported contralateral malignancies detected only by MRI in 131 of 3,253 women. Summary estimates were as follows: MRI-detected suspicious findings (TP plus FP), 9.3% (95% CI, 5.8% to 14.7%); ICDR, 4.1% (95% CI, 2.7% to 6.0%), PPV, 47.9% (95% CI, 31.8% to 64.6%); TP:FP ratio, 0.92 (95% CI, 0.47 to 1.82). PPV was associated with the number of test positives and baseline imaging. Few studies included consecutive women, and few ascertained outcomes in all subjects. Where reported, 35.1% of MRI-detected cancers were ductal carcinoma in situ (mean size = 6.9 mm), 64.9% were invasive cancers (mean size = 9.3 mm), and the majority were stage pTis or pT1 and node negative. Effect on treatment was inconsistently reported, but many women underwent contralateral mastectomy. Conclusion MRI detects contralateral lesions in a substantial proportion of women, but does not reliably distinguish benign from malignant findings. Relatively high ICDR may be due to selection bias and/or overdetection. Women must be informed of the uncertain benefit and potential harm, including additional investigations and surgery.